BioHarvest Sciences (NASDAQ:BHST) Trading 2.8% Higher - Should You Buy?

Key Points

• BioHarvest Sciences shares rose 2.8% to $8.18, despite a significant drop in trading volume, down 72% from the average session.
• Analysts at Craig Hallum initiated coverage with a buy rating and a target price of $15.00, contributing to an average price target of $13.67 across three research analysts.
• The company reported a loss of ($0.15) EPS for the last quarter, missing expectations, and has set its EPS guidance at -0.8 for the current year.

BioHarvest Sciences Inc. (NASDAQ:BHST - Get Free Report)'s share price shot up 2.8% during mid-day trading on Monday . The stock traded as high as $8.35 and last traded at $8.18. 5,931 shares traded hands during trading, a decline of 72% from the average session volume of 21,171 shares. The stock had previously closed at $7.96.

Wall Street Analyst Weigh In

Separately, Craig Hallum began coverage on shares of BioHarvest Sciences in a report on Monday, May 5th. They set a "buy" rating and a $15.00 target price on the stock. Three research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has an average rating of "Buy" and an average target price of $13.67.

BioHarvest Sciences Stock Performance

The company's fifty day simple moving average is $7.77 and its 200-day simple moving average is $6.72. The company has a market capitalization of $134.32 million, a P/E ratio of -11.69 and a beta of 0.68.

BioHarvest Sciences (NASDAQ:BHST - Get Free Report) last issued its earnings results on Monday, August 11th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.04). BioHarvest Sciences had a negative return on equity of 11,357.84% and a negative net margin of 39.95%.The business had revenue of $8.52 million for the quarter, compared to the consensus estimate of $8.53 million. BioHarvest Sciences has set its Q3 2025 guidance at EPS. On average, sell-side analysts predict that BioHarvest Sciences Inc. will post -0.8 EPS for the current year.

Institutional Trading of BioHarvest Sciences

An institutional investor recently raised its position in BioHarvest Sciences stock. Magnus Financial Group LLC raised its position in shares of BioHarvest Sciences Inc. (NASDAQ:BHST - Free Report) by 105.0% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 71,733 shares of the company's stock after buying an additional 36,733 shares during the quarter. Magnus Financial Group LLC owned about 0.44% of BioHarvest Sciences worth $444,000 at the end of the most recent reporting period.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.